Bristol Myers Squibb Co (CELG-RI) — SEC Filings
Bristol Myers Squibb Co (CELG-RI) — 33 SEC filings. Latest: 8-K (Nov 18, 2025). Includes 16 8-K, 6 10-Q, 3 DEFA14A.
View Bristol Myers Squibb Co on SEC EDGAR
Overview
Bristol Myers Squibb Co (CELG-RI) is a publicly traded company tracked on ReadTheFiling. The most recent enriched filing is a 8-K filed on Nov 18, 2025: Bristol Myers Squibb Company announced on November 17, 2025, the issuance of new senior notes. These include $3.857 billion in notes due 2038, $4.581 billion due 2055, $3.363 billion due 2033, $4.289 billion due 2045, and $1.750 billion due 2035. The company also issued $2.973 billion in notes due 2
Sentiment Summary
Across 33 filings, the sentiment breakdown is: 2 bullish, 29 neutral, 2 mixed. The dominant filing sentiment for Bristol Myers Squibb Co is neutral.
Filing Type Overview
Bristol Myers Squibb Co (CELG-RI) has filed 16 8-K, 6 10-Q, 3 DEFA14A, 2 DEF 14A, 2 10-K, 3 SC 13G/A, 1 SC 13G with the SEC between Jan 2024 to Nov 2025.
Filings by Year
Recent SEC Filings (33)
Risk Profile
Risk Assessment: Of CELG-RI's 26 recent filings, 0 were flagged as high-risk, 11 as medium-risk, and 15 as low-risk. The overall risk profile suggests relatively low risk with generally favorable filings.
Financial Highlights
| Metric | Value |
|---|---|
| Revenue | $12.222B |
| Net Income | $2.201B |
| EPS | $1.08 |
| Debt-to-Equity | 1.24 |
| Cash Position | $15.726B |
| Operating Margin | 25.7% |
| Total Assets | $96.889B |
| Total Debt | $48.978B |
Key Executives
- Dr. Giovanni Caforio
- Dr. Chris Boerner
- Dr. Samit Hirawat
- Dr. Lamberto Andreotti
- Ms. Susan L. Solomon
- David M. Denton
Industry Context
The pharmaceutical industry continues to be characterized by intense competition, significant R&D investment, and evolving regulatory landscapes. Companies are increasingly focused on specialty drugs, particularly in oncology and immunology, to drive growth. The trend towards strategic acquisitions and partnerships, as seen with BMS's payments to BioNTech and SystImmune, is prevalent as firms seek to bolster their pipelines and address patent cliffs.
Top Tags
pharmaceuticals (6) · corporate-governance (5) · debt (5) · debt-issuance (4) · proxy-statement (4) · Pharmaceuticals (3) · sec-filing (3) · financial-reporting (3) · revenue (3) · Bristol Myers Squibb (3)
Key Numbers
| Metric | Value | Context |
|---|---|---|
| Notes Due 2038 | $3.857B | Part of a large debt issuance |
| Notes Due 2055 | $4.581B | Part of a large debt issuance |
| Notes Due 2033 | $3.363B | Part of a large debt issuance |
| Notes Due 2045 | $4.289B | Part of a large debt issuance |
| Notes Due 2035 | $1.750B | Part of a large debt issuance |
| Notes Due 2030 | $2.973B | Part of a large debt issuance |
| Net earnings attributable to BMS | $2.201B | Increased 81.75% for Q3 2025 compared to Q3 2024 |
| Total Revenues | $12.222B | Increased 2.77% for Q3 2025 |
| Total Growth Portfolio sales | $6.857B | Increased 17.98% for Q3 2025 |
| Total Legacy Portfolio sales | $5.365B | Decreased 11.89% for Q3 2025 |
| Opdivo sales | $2.532B | Increased 7.29% for Q3 2025 |
| Eliquis sales | $3.746B | Increased 24.78% for Q3 2025 |
| Revlimid sales | $575M | Decreased 59.28% for Q3 2025 |
| Upfront payment to BioNTech | $1.5B | Recorded as Acquired IPRD in Q3 2025 |
| Development milestone to SystImmune | $250M | Recorded as Acquired IPRD in Q3 2025 |
Related Companies
Frequently Asked Questions
What are the latest SEC filings for Bristol Myers Squibb Co (CELG-RI)?
Bristol Myers Squibb Co has 33 recent SEC filings from Jan 2024 to Nov 2025, including 16 8-K, 6 10-Q, 3 DEFA14A. Each filing includes an AI-generated plain-English summary.
What is the overall sentiment of CELG-RI filings?
Across 33 filings, the sentiment breakdown is: 2 bullish, 29 neutral, 2 mixed. The dominant sentiment is neutral.
Where can I find Bristol Myers Squibb Co SEC filings explained simply?
ReadTheFiling provides AI-powered plain-English summaries of all Bristol Myers Squibb Co (CELG-RI) SEC filings, including 10-K annual reports, 10-Q quarterly reports, 8-K current reports, and insider trades.
What are the key financial highlights for Bristol Myers Squibb Co?
Key financial highlights from Bristol Myers Squibb Co's most recent 10-Q include metrics such as revenue, net income, EPS, and debt ratios. Visit the filing detail page for the full breakdown.
What is the investment thesis for CELG-RI?
The investment thesis for CELG-RI includes bull, base, and bear case scenarios derived from AI analysis of recent SEC filings.
Who are the key executives at Bristol Myers Squibb Co?
Key executives identified across Bristol Myers Squibb Co's filings include Dr. Giovanni Caforio, Dr. Chris Boerner, Dr. Samit Hirawat, Dr. Lamberto Andreotti, Ms. Susan L. Solomon and 1 others.
What are the main risk factors for Bristol Myers Squibb Co stock?
Of CELG-RI's 26 assessed filings, 0 were flagged high-risk, 11 medium-risk, and 15 low-risk.
What are recent predictions and forward guidance from Bristol Myers Squibb Co?
Forward guidance and predictions for Bristol Myers Squibb Co are extracted from SEC filings as they are enriched.